Renascience <4889>

Revision of financial estimates for the year ending March 2025 announced. Revenue has been revised upward from 0.09 billion yen to 0.105 billion yen, and operating loss has been revised upward from a loss of 0.275 billion yen to a loss of 0.257 billion yen, due to the start of Phase 1 clinical trials at Eirion Therapeutics, Inc. in the United States and the expected receipt of a milestone payment of $ 0.1 million from Eirion Therapeutics.

GMO <9449>

Due to a rapid decline from the high of 2800.5 yen on May 16th, the stock price fell below the 200-day moving average and has continued to move within a range with the same line as a resistance. However, it has rebounded from the low of 2368 yen on June 17th and is approaching the upper limit of the range. Recently, as the 25-day moving average is seen as a support line, aim for a stance to break through the 200-day moving average.